Labixiaoxin Snacks Group Limited Stocks

HK$ 3.69Last Updated 28.04.2026

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

HK$ 112.67M

Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
HK$ 3.69
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Labixiaoxin Snacks Group Limited, an investment holding company, manufactures and sells jelly, confectionary, beverage, and other snack products in the People's Republic of China. It offers jelly snacks, such as fruit-flavored, canned fruit, yogurt, and mousse jellies; jelly beverages; lollipops, milk and gummy candies, and chocolates; fruit and vegetable beverages; and powdered milk tea, dried bean curd, and baked and beverage products under the Labixiaoxin, Sunshine City, Humor, and Xiangdoufang brands. The company was formerly known as China Lifestyle Food and Beverages Group Limited and changed its name to Labixiaoxin Snacks Group Limited in June 2012. The company was founded in 2000 and is headquartered in Jinjiang, the People's Republic of China. Labixiaoxin Snacks Group Limited is a subsidiary of Alliance Food and Beverages (Holding) Company Limited.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is overvalued on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks